Given the critical role of the COX-2/PGE2 axis in GBM, therapeutic targeting of this pathway offers potential benefits, including reduced cell proliferation, angiogenesis, and enhanced apoptosis [17,18]. The gene discussed is PTGS2; the disease is glioblastoma.